{"id":2053,"text":"Quantitative prediction of herb–drug interaction risk remains challenging.","label":[],"Comments":[]}
{"id":2054,"text":"A quantitative framework to assess a potential interaction was used to evaluate a mechanism not previously tested in humans.","label":[],"Comments":[]}
{"id":2055,"text":"The semipurified milk thistle product, silibinin, was selected as an exemplar herbal product inhibitor of raloxifene intestinal glucuronidation.","label":[[0,48,"Herb name"],[4,16,"Extraction process"],[106,116,"Drug"],[106,143,"Parameter"]],"Comments":[]}
{"id":2056,"text":"Physiologically based pharmacokinetic (PBPK) model simulations of the silibinin–raloxifene interaction predicted up to 30% increases in raloxifene area under the curve (AUC   WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?","label":[[70,79,"Herb name"],[80,90,"Drug"],[119,132,"Amount"],[136,146,"Drug"],[136,172,"Parameter"]],"Comments":[]}
{"id":2057,"text":"☑ Herbal products may perpetrate untoward interactions with conventional drugs via numerous mechanisms.","label":[[2,17,"Herb name"],[60,78,"Drug"]],"Comments":[]}
{"id":2058,"text":"One potential mechanism, inhibition of intestinal glucuronidation, has been reported in preclinical models, but the clinical relevance of these observations is unexplored.","label":[[39,65,"Parameter"],[88,106,"Study"]],"Comments":[]}
{"id":2059,"text":"• WHAT QUESTION DID THIS STUDY ADDRESS?","label":[],"Comments":[]}
{"id":2060,"text":"☑ This study addressed the application of a PBPK modeling approach to predict an herb–drug interaction mediated via inhibition of intestinal glucuronidation, an uncharted mechanism in humans.","label":[[130,156,"Parameter"]],"Comments":[]}
{"id":2061,"text":"The approach was evaluated via a proof‐of‐concept clinical study using silibinin as an exemplar herbal product perpetrator and raloxifene as an intestinal UGT probe victim.","label":[[50,64,"Study"],[71,80,"Herb name"],[96,110,"Herb name"],[127,137,"Drug"],[144,158,"Parameter"]],"Comments":[]}
{"id":2062,"text":"• WHAT THIS STUDY ADDS TO OUR KNOWLEDGE ☑ A mechanistic PBPK interaction model accurately predicted the minimal impact of the silibinin–raloxifene interaction.","label":[[126,135,"Herb name"],[136,146,"Drug"]],"Comments":[]}
{"id":2063,"text":"This study demonstrates the utility of PBPK modeling and simulation to predict herb–drug interactions mediated via alternate mechanisms.","label":[],"Comments":[]}
{"id":2064,"text":"• HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS ☑ These approaches can be used to establish paradigms for the prospective evaluation of herb–drug interaction potential that will provide evidence‐based information about the risk or safety of herb–drug combinations.","label":[],"Comments":[]}
{"id":2065,"text":"Herbal product usage rates continue to climb, fueled in part by the common misperception that “natural” is synonymous with “safe.” Consumers often turn to these products as a means to alleviate self‐diagnosed illnesses or supplement prescribed therapeutic regimens.","label":[[0,14,"Herb name"],[194,219,"Pathology"]],"Comments":[]}
{"id":2066,"text":"As a result, herbal products are frequently taken by patients in conjunction with prescribed and over‐the‐counter medications, triggering potential unwanted herb–drug interactions.","label":[[13,28,"Herb name"]],"Comments":[]}
{"id":2067,"text":"Drug interaction liability assessment of herbal products is inherently more complicated than for conventional drugs due to their complex composition and relatively scant knowledge of individual constituents that perpetrate these interactions.","label":[[41,56,"Herb name"],[97,115,"Drug"]],"Comments":[]}
{"id":2068,"text":"A robust approach that identifies causative constituents, characterizes the pharmacokinetics of those constituents, and describes herb–drug interactions mechanistically is nonexistent.","label":[],"Comments":[]}
{"id":2069,"text":"Consequently, in vitro–in vivo disconnects are more the norm than the exception when translating herb–drug interaction predictions to the clinic.","label":[],"Comments":[]}
{"id":2070,"text":"Physiologically based pharmacokinetic (PBPK) modeling and simulation has been proposed as a means to improve the quantitative prediction of herb–drug interactions.1, 2 This framework has been applied to interactions mediated via inhibition of cytochrome P450 enzymes,2 but investigation of alternate mechanisms that underlie herb–drug interactions remain relatively unexplored.","label":[[243,266,"Target"]],"Comments":[]}
{"id":2071,"text":"Inhibition of intestinal UDP‐glucuronosyl transferases (UGTs) represents one such potential mechanism3, 4 based on in vitro and animal studies.3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 Taken together, a PBPK modeling and simulation approach2 was expanded by applying to a an herb–drug interaction mediated via inhibition of intestinal glucuronidation, a mechanism not previously evaluated in humans.","label":[[14,61,"Target"],[115,142,"Study"],[323,349,"Parameter"]],"Comments":[]}
{"id":2072,"text":"Milk thistle (Silybum marianum (L.) Gaertn (Asteraceae)) is a popular herbal product widely used as a hepatoprotectant or cancer chemopreventive agent.16, 17 Silibinin, a semipurified milk thistle seed extract consisting of roughly a 1:1 mixture of the flavonolignans silybin A and silybin B,18 was selected as an exemplar perpetrator of herb–drug interactions due to a well‐characterized composition, sufficient quantities of individual constituents available to recover in vitro kinetic parameters, and available human pharmacokinetic data to assess model predictions.16, 17 Raloxifene, a blockbuster selective estrogen receptor modulator (SERM), was selected as a clinically relevant exemplar intestinal UGT substrate to elucidate the potential for altered drug disposition in humans via inhibition of intestinal glucuronidation.","label":[[0,56,"Herb name"],[122,128,"Pathology"],[158,209,"Herb name"],[171,183,"Extraction process"],[197,201,"Herb part"],[253,291,"Herb name"],[472,499,"Parameter"],[577,647,"Drug"],[613,630,"Parameter"],[696,710,"Parameter"],[805,831,"Parameter"]],"Comments":[]}
{"id":2073,"text":"Raloxifene is extensively metabolized by intestinal UGTs, particularly UGTs 1A8 and 1A10.19, 20, 21, 22, 23 Silibinin potently inhibited these UGTs in vitro (K PBPK models were developed for raloxifene, silybin A, and silybin B using the general purpose differential equation solver, Berkeley Madonna (v. 8.3; University of California at Berkeley, Berkeley, CA), and the population‐based simulator, SimCYP (v. 13.2; SimCYP, Sheffield, UK).","label":[[0,10,"Drug"],[41,88,"Parameter"],[108,117,"Herb name"],[143,147,"Target"],[191,201,"Drug"],[203,227,"Herb name"]],"Comments":[]}
{"id":2074,"text":"Two modeling and simulation platforms were assessed because standard approaches for the prediction of UGT‐mediated interactions have not been developed.","label":[[102,105,"Parameter"]],"Comments":[]}
{"id":2075,"text":"The Berkeley Madonna base model structure was adapted from the literature,2 incorporating raloxifene and silibinin kinetic (K Physiologically based pharmacokinetic model input parameters See “Methods” for detailed information on model parameterization.","label":[[90,100,"Drug"],[105,114,"Herb name"]],"Comments":[]}
{"id":2076,"text":"k The PBPK model for perpetrator (silybin A and silybin B) and victim (raloxifene) were linked through the reversible inhibition of raloxifene intestinal glucuronidation (supplemental figure 2).","label":[[34,57,"Herb name"],[71,81,"Drug"],[132,142,"Drug"],[132,170,"Parameter"]],"Comments":[]}
{"id":2077,"text":"Initial simulations used doses of raloxifene and silibinin products reported in previous studies.","label":[[34,44,"Drug"],[49,58,"Herb name"]],"Comments":[]}
{"id":2078,"text":"Observed concentration–time profiles were extracted from the literature using GetData Graph Digitizer (v. 2.26).","label":[[9,36,"Parameter"]],"Comments":[]}
{"id":2079,"text":"Simulations were evaluated by visual inspection of predicted and observed concentration–time profiles and comparison of predicted to observed primary pharmacokinetic endpoints (AUC Mean concentration–time profile of raloxifene following a single 60 mg oral dose.","label":[[74,101,"Parameter"],[177,226,"Parameter"],[216,226,"Drug"],[237,261,"Frequency"],[246,251,"Amount"]],"Comments":[]}
{"id":2080,"text":"Solid lines denote physiologically based pharmacokinetic model simulations using Berkeley Madonna (a) or SimCYP (b).","label":[],"Comments":[]}
{"id":2081,"text":"Dashed lines denote upper and lower 90% confidence intervals (b).","label":[],"Comments":[]}
{"id":2082,"text":"Open symbols denote observed means and were obtained from ref.","label":[],"Comments":[]}
{"id":2083,"text":"36.","label":[],"Comments":[]}
{"id":2084,"text":"Siliphos capsules (n = 10) (Thorne Research, Dover, ID) were analyzed using previously described methods2 to ensure purity and content.","label":[[0,17,"Herb name"]],"Comments":[]}
{"id":2085,"text":"In brief, the contents of each capsule were weighed and extracted twice with 2 mL acetone.","label":[[77,81,"Amount"],[82,89,"Extraction process"]],"Comments":[]}
{"id":2086,"text":"The extract was vortex‐mixed and centrifuged (13,000g × 2 minutes).","label":[],"Comments":[]}
{"id":2087,"text":"The supernatant was transferred to a clean vial for analysis of milk thistle flavonolignans using an Acquity UPLC system with an HSS‐T3 (1.8 µm, 2.1 × 100 mm) column (Waters, Milford, MA).","label":[[64,91,"Herb name"]],"Comments":[]}
{"id":2088,"text":"Flavonolignan standards31 and Siliphos capsule extracts were analyzed using Empower 3 software with a gradient from 30:70 to 55:45 methanol:water (0.1% formic acid) over 6.0 minutes at a flow rate of 0.5 mL\/min at 50°C; peaks were detected at 288 nm.","label":[[0,13,"Herb name"],[30,55,"Herb name"],[131,164,"Extraction process"],[165,181,"Duration"],[200,210,"Frequency"],[214,216,"Amount"],[216,218,"Parameter"]],"Comments":[]}
{"id":2089,"text":"Healthy volunteers (eight men, eight nonpregnant women) were enrolled in an open‐label, single‐dose, randomized two‐period crossover study conducted at the Washington State University (WSU) Clinical Research Unit (CRU) (Supplemental Figure 1).","label":[[0,7,"Pathology"],[20,54,"Ethnic group"],[26,29,"Sex"],[37,48,"Parameter"],[49,54,"Sex"],[73,138,"Study"]],"Comments":[]}
{"id":2090,"text":"The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.","label":[],"Comments":[]}
{"id":2091,"text":"Eligibility to participate was based on screening evaluation and inclusion\/exclusion criteria (Supplemental Table 1).","label":[],"Comments":[]}
{"id":2092,"text":"Potential subjects provided written informed consent and Health Insurance Portability and Accountability Act authorization before undergoing screening, which consisted of the following: medical history, physical examination, liver function tests, complete blood count, and urinalysis.","label":[],"Comments":[]}
{"id":2093,"text":"All women underwent a serum pregnancy test.","label":[[4,9,"Sex"],[28,37,"Parameter"]],"Comments":[]}
{"id":2094,"text":"Eligible participants were randomized to enter the control or treatment phase using a blocked design to ensure equal numbers of men and women in each sequence.","label":[[128,131,"Sex"],[136,141,"Sex"]],"Comments":[]}
{"id":2095,"text":"The randomization schedule was created using SAS PROC PLAN (v. 9.2; SAS Institute, Cary, NC).","label":[],"Comments":[]}
{"id":2096,"text":"The control phase involved administration of 60 mg raloxifene (Teva Pharmaceuticals, Sellersville, PA) (Supplemental Figure 1).","label":[[45,50,"Amount"],[51,61,"Drug"]],"Comments":[]}
{"id":2097,"text":"Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.","label":[[0,54,"Parameter"],[72,87,"Frequency"]],"Comments":[]}
{"id":2098,"text":"Blood (7 mL) was collected in BD Vacutainer tubes containing EDTA (Becton, Dickinson, Franklin Lakes, NJ) through an intravenous line before and from 0.25–12 hours following drug administration.","label":[[145,163,"Duration"]],"Comments":[]}
{"id":2099,"text":"Subjects continued to fast until after the 4‐hour blood collection, when meals and snacks, devoid of fruit juices and caffeine‐containing products, were provided.","label":[[22,26,"Parameter"],[43,49,"Duration"],[101,106,"Herb part"],[107,113,"Extraction process"],[118,126,"Herb name"]],"Comments":[]}
{"id":2100,"text":"Subjects returned to the CRU 24, 48, 72, and 96 hours postdrug administration for blood collection via venipuncture.","label":[[29,53,"Duration"]],"Comments":[]}
{"id":2101,"text":"Plasma (∼3 mL) was harvested by centrifugation and collected in cryogenic vials (Corning, Tewksbury, MA) (∼1 mL each) for storage at −80°C pending analysis by UHPLC‐MS\/MS.","label":[],"Comments":[]}
{"id":2102,"text":"At least a seven‐day washout period separated each phase (Supplemental Figure 1).","label":[[9,35,"Duration"]],"Comments":[]}
{"id":2103,"text":"The treatment phase involved administration of 60 mg raloxifene followed immediately by 480 mg Siliphos (based on labeled content) three times daily for the entire collection interval.","label":[[47,52,"Amount"],[53,63,"Drug"],[88,94,"Amount"],[95,103,"Herb name"],[131,148,"Frequency"]],"Comments":[]}
{"id":2104,"text":"Each subject received his\/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.","label":[[30,38,"Herb name"],[150,191,"Parameter"],[197,211,"Pathology"]],"Comments":[]}
{"id":2105,"text":"Subjects were instructed how to use the blister pack properly, and compliance was assessed at each study visit.","label":[],"Comments":[]}
{"id":2106,"text":"Plasma collection times and procedures mirrored those outlined for the control phase.","label":[],"Comments":[]}
{"id":2107,"text":"Plasma (100 µL) was treated with methanol (4 volumes with 0.1% formic acid) containing the internal standards raloxifene‐d Pharmacokinetic outcomes were recovered by noncompartmental analysis using Phoenix WinNonlin.","label":[[33,74,"Extraction process"],[110,122,"Drug"]],"Comments":[]}
{"id":2108,"text":"Concentrations below the limit of quantification for each analyte were excluded.","label":[[0,14,"Parameter"]],"Comments":[]}
{"id":2109,"text":"The terminal elimination rate constant (λ All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).","label":[],"Comments":[]}
{"id":2110,"text":"The sample size for the proof‐of‐concept study (n = 16 evaluable subjects) was calculated based on 80% power to detect a 25% change in the primary endpoints with a Type I error of 0.05; the primary endpoint was the test\/reference ratio of log‐transformed raloxifene AUC Simulated raloxifene concentration–time profiles closely approximated previously published model predictions,26 observed profiles,36, 37 and reported pharmacokinetic outcomes.35 Model‐predicted primary endpoints, raloxifene AUC Comparison of previously published and model‐predicted raloxifene pharmacokinetic outcomes     t Simulations conducted using Berkeley Madonna predicted an ∼30% increase in raloxifene AUC Comparison of clinical study outcomes to physiologically based pharmacokinetic model predictions R4G, raloxifene‐4′‐glucuronide; R6G, raloxifene‐6‐glucuronide; t *Paired two‐tailed Student's t‐test on log‐transformed data (control vs. treatment).","label":[[20,46,"Study"],[48,73,"Cohort"],[255,265,"Drug"],[255,269,"Parameter"],[280,290,"Drug"],[280,318,"Parameter"],[483,493,"Drug"],[483,497,"Parameter"],[553,563,"Drug"],[670,680,"Drug"],[670,684,"Parameter"],[699,713,"Study"],[782,812,"Drug"],[814,843,"Drug"]],"Comments":[]}
{"id":2111,"text":"A single lot (#313823) of Siliphos capsules, labeled to contain 60 mg silibinin per capsule, was selected as the test herbal product.","label":[[26,43,"Herb name"],[64,69,"Amount"],[70,79,"Herb name"]],"Comments":[]}
{"id":2112,"text":"The capsules were overfilled consistently, containing 73.4 ± 2.47 mg silibinin comprised of 31.3 ± 0.84 mg silybin A and 42.1 ± 1.97 mg silybin B.","label":[[54,68,"Amount"],[69,78,"Herb name"],[92,106,"Amount"],[107,116,"Herb name"],[121,135,"Amount"],[136,145,"Herb name"]],"Comments":[]}
{"id":2113,"text":"The capsules also contained small amounts of the regioisomers isosilybin A (1.21 ± 0.03 mg) and isosilybin B (1.01 ± 0.06 mg).","label":[[45,74,"Herb name"],[76,90,"Amount"],[96,108,"Herb name"],[110,124,"Amount"]],"Comments":[]}
{"id":2114,"text":"Prior to the first study day, two participants (one man, one woman) withdrew consent due to unforeseen scheduling conflicts.","label":[[52,55,"Sex"],[61,66,"Sex"]],"Comments":[]}
{"id":2115,"text":"Two additional participants were screened, enrolled, and assigned to the randomization schedule of the participants they replaced.","label":[],"Comments":[]}
{"id":2116,"text":"All participants who entered the study completed both phases (Supplemental Table 2).","label":[],"Comments":[]}
{"id":2117,"text":"Raloxifene and Siliphos were well tolerated.","label":[[0,10,"Drug"],[15,23,"Herb name"]],"Comments":[]}
{"id":2118,"text":"One subject experienced nausea in response to venous catheter placement that was self‐limiting and not study drug‐related (occurred prior to administration).","label":[[24,30,"Pathology"],[46,71,"Parameter"]],"Comments":[]}
{"id":2119,"text":"The event did not limit the subject's continued participation.","label":[],"Comments":[]}
{"id":2120,"text":"No other adverse events were reported.","label":[[9,23,"Pathology"]],"Comments":[]}
{"id":2121,"text":"The effects of silibinin (480 mg three times daily × 4 days) were compared to baseline oral pharmacokinetics of raloxifene (control phase).","label":[[15,24,"Herb name"],[26,32,"Amount"],[33,50,"Frequency"],[53,59,"Duration"],[87,123,"Parameter"],[112,122,"Drug"]],"Comments":[]}
{"id":2122,"text":"Silibinin did not alter raloxifene C Geometric mean concentration–time profile of (a) raloxifene, (b) raloxifene‐4′‐glucuronide (R4G), and (c) raloxifene‐6‐glucuronide (R6G) following a single 60 mg oral dose of raloxifene given alone (open symbols) or after silibinin (480 mg three times daily × 4 days) treatment (solid symbols).","label":[[0,9,"Herb name"],[24,34,"Drug"],[24,36,"Parameter"],[37,173,"Parameter"],[86,96,"Drug"],[102,133,"Drug"],[143,173,"Drug"],[184,208,"Frequency"],[193,198,"Amount"],[212,222,"Drug"],[259,268,"Herb name"],[270,276,"Amount"],[277,294,"Frequency"],[297,303,"Duration"]],"Comments":[]}
{"id":2123,"text":"Lines in (a) denote PBPK model simulations of raloxifene concentration–time profiles when given alone (solid line) or with silibinin (dashed line) using Berkeley Madonna (gray) or SimCYP (crimson).","label":[[46,56,"Drug"],[46,84,"Parameter"],[123,132,"Herb name"]],"Comments":[]}
{"id":2124,"text":"R6G concentrations are not reported beyond 72 hours due to concentrations being below the lower limit of quantitation (c).","label":[[0,3,"Drug"],[0,18,"Parameter"],[43,51,"Duration"],[59,73,"Parameter"]],"Comments":[]}
{"id":2125,"text":"Symbols and error bars denote observed geometric means and upper limits of the 90% confidence interval, respectively.","label":[],"Comments":[]}
{"id":2126,"text":"Effects of silibinin (480 mg three times daily for 4 days) on (a,c,e) C Pharmacokinetic outcomes for the raloxifene glucuronides were minimally altered by silibinin (<10%).","label":[[11,21,"Herb name"],[22,28,"Amount"],[29,46,"Frequency"],[47,57,"Duration"],[101,128,"Drug"],[155,164,"Herb name"],[166,170,"Amount"]],"Comments":[]}
{"id":2127,"text":"Relative to control, geometric mean R4G C The sampling strategy was not intended to capture silybin A and silybin B pharmacokinetics; as such, these outcomes are presented for qualitative purposes.","label":[[36,39,"Drug"],[36,41,"Parameter"],[92,101,"Herb name"],[92,132,"Parameter"],[106,115,"Herb name"]],"Comments":[]}
{"id":2128,"text":"Silybin A and silybin B were rapidly eliminated (geometric mean t Geometric mean concentration–time profiles of silybin A (gray circles) and silybin B (crimson triangles) following oral administration of silibinin (480 mg three times daily × 4 days).","label":[[0,23,"Herb name"],[81,150,"Parameter"],[112,121,"Herb name"],[141,150,"Herb name"],[204,213,"Herb name"],[215,221,"Amount"],[222,239,"Frequency"],[242,248,"Duration"]],"Comments":[]}
{"id":2129,"text":"Solid lines denote PBPK model simulations of mean concentration–time profiles using Berkeley Madonna (a) or SimCYP (b).","label":[[45,77,"Parameter"]],"Comments":[]}
{"id":2130,"text":"Dashed lines denote upper and lower 90% confidence intervals (b).","label":[],"Comments":[]}
{"id":2131,"text":"Symbols and error bars denote observed geometric means and upper limits of the 90% confidence interval, respectively.","label":[],"Comments":[]}
{"id":2132,"text":"Despite considerable investigation, quantitative prediction of herb–drug interaction liability remains elusive.","label":[],"Comments":[]}
{"id":2133,"text":"Regulatory guidelines in Western countries typically require premarket evaluation of drug–drug interactions, but these guidelines generally do not apply to herb–drug interactions.","label":[],"Comments":[]}
{"id":2134,"text":"Approaches developed for the prediction of drug–drug interactions are often inadequate to overcome the additional hurdles unique to the evaluation of herb–drug interactions.1, 39, 40, 41 The complex composition of herbal products renders traditional static models of drug–drug interaction potential generally less useful for the prediction of herb–drug interactions.","label":[],"Comments":[]}
{"id":2135,"text":"Highly variable and limited pharmacokinetic data available for herbal constituents, combined with a lack of herbal product standardization, continues to challenge the development of predictive herb–drug interaction models.","label":[[108,122,"Herb name"]],"Comments":[]}
{"id":2136,"text":"Consequently, approaches to assess herb–drug interaction liability vary widely, yielding conflicting results, inconclusive translation to the clinical setting, and uncertain generalizability.","label":[],"Comments":[]}
{"id":2137,"text":"The relative paucity of reliable pharmacokinetic data to describe herbal product constituents further complicates efforts to extrapolate preclinical data to predict clinical consequences.","label":[],"Comments":[]}
{"id":2138,"text":"PBPK modeling and simulation approaches have been suggested as a method to predict the consequences of drug–drug and herb–drug interactions mediated via modulation of CYP‐mediated metabolism.2, 33, 34 SimCYP, a population‐based PBPK simulation platform, is designed explicitly to predict the absorption, distribution, metabolism, and excretion (ADME) of drug molecules and their interplay with xenobiotics that can modulate one or more of these processes.","label":[[167,190,"Parameter"],[289,368,"Parameter"],[394,405,"Parameter"]],"Comments":[]}
{"id":2139,"text":"The intuitive user interface of SimCYP provides a means to populate built‐in model structures and generate simulated pharmacokinetic outcomes that can be output in a standard format.","label":[],"Comments":[]}
{"id":2140,"text":"However, the built‐in model structures are limited in that a maximum of two perpetrators can be accommodated.","label":[],"Comments":[]}
{"id":2141,"text":"This limitation applies particularly to the prediction of herb–drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.","label":[[85,100,"Herb name"],[164,178,"Parameter"]],"Comments":[]}
{"id":2142,"text":"In contrast, Berkeley Madonna is a general‐purpose differential equation solver that is limited in terms of model structures and perpetrator count only by the user's ability to adequately describe these processes mathematically.","label":[],"Comments":[]}
{"id":2143,"text":"This flexibility, however, is accompanied by a lack of functionality to easily incorporate population and parameter variability and generate standardized outputs.","label":[],"Comments":[]}
{"id":2144,"text":"These limitations may require additional software platforms to generate desired outcome measures and evaluate the impact of population and parameter uncertainty.","label":[],"Comments":[]}
{"id":2145,"text":"Based on these advantages and disadvantages of SimCYP and Berkeley Madonna, both platforms were used and expanded with unique approaches to evaluate the consequences of an herb–drug interaction mediated via inhibition of intestinal glucuronidation, a mechanism uncharted in humans.","label":[[221,247,"Parameter"]],"Comments":[]}
{"id":2146,"text":"Silibinin was selected as a model herbal product perpetrator based on well‐characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb–drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin–raloxifene interaction.","label":[[0,9,"Herb name"],[34,48,"Herb name"],[271,297,"Parameter"],[423,432,"Herb name"],[433,443,"Drug"]],"Comments":[]}
{"id":2147,"text":"The Berkeley Madonna model incorporated data recovered from human microsomal systems,25 which contain the full complement of UGTs present in the intestine and liver.","label":[[125,129,"Parameter"]],"Comments":[]}
{"id":2148,"text":"This approach illustrates the impact of modulation of overall intestinal raloxifene glucuronidation.","label":[[62,99,"Parameter"],[73,83,"Drug"]],"Comments":[]}
{"id":2149,"text":"The SimCYP model incorporated data from HEK293 cell lysates25 to describe the UGT isoform‐specific inhibition of raloxifene glucuronidation.","label":[[78,89,"Parameter"],[113,123,"Drug"],[113,139,"Parameter"]],"Comments":[]}
{"id":2150,"text":"Both models provided an accurate bottom‐up description of raloxifene pharmacokinetics.","label":[[58,68,"Drug"],[58,85,"Parameter"]],"Comments":[]}
{"id":2151,"text":"These data are consistent with the assertion that in vitro to in vivo extrapolation accuracy for UGT substrates is improved by incorporating parameters to describing drug disposition in multiple organs with metabolic capacity.20, 42 Raloxifene modulation of silibinin disposition via competitive inhibition was not incorporated into model predictions, as quantitative data (K The Berkeley Madonna interaction model overpredicted, whereas the SimCYP interaction model accurately predicted, the observed magnitude of interaction.","label":[[97,100,"Parameter"],[233,243,"Drug"],[258,267,"Herb name"]],"Comments":[]}
{"id":2152,"text":"The discrepancy between the two models can be partially explained by the different in vitro parameters used to populate each model.","label":[],"Comments":[]}
{"id":2153,"text":"The differing absorption models also may contribute.","label":[],"Comments":[]}
{"id":2154,"text":"The Berkeley Madonna model used a relatively simple first‐order absorption model, whereas the SimCYP model used the advanced dissolution, absorption, and metabolism (ADAM) model.","label":[],"Comments":[]}
{"id":2155,"text":"The ADAM model incorporates population variability of multiple component processes within a mechanistic framework to describe the passage of drug molecules along and through the gastrointestinal tract.30 The ADAM model divides the intestine into multiple transit compartments, effectively distributing any interactions between the herbal product perpetrator, silibinin, and the victim drug, raloxifene, along the entire length of the gastrointestinal tract.","label":[[327,368,"Herb name"],[374,401,"Drug"]],"Comments":[]}
{"id":2156,"text":"The net interaction potential reflects a summary of multiple processes governing the release, dissolution, permeability, metabolism, and transit of both the perpetrator and victim.","label":[[81,179,"Parameter"]],"Comments":[]}
{"id":2157,"text":"In contrast, the Berkeley Madonna model assumes that the interaction occurs within a single, homogenous compartment.","label":[],"Comments":[]}
{"id":2158,"text":"This assumption can result in overprediction of inhibitor concentration and residence time at the active site and may explain the overprediction of the interaction magnitude by the Berkeley Madonna model.","label":[[48,71,"Parameter"],[76,109,"Parameter"]],"Comments":[]}
{"id":2159,"text":"A mechanistic static model of the silibinin–raloxifene interaction predicted up to a 5‐fold increase in raloxifene systemic exposure in the presence of silibinin.25 However, dynamic modeling and simulation more accurately predicted the observed lack of clinical interaction and provided another example of overprediction by a static model of interaction risk for rapidly cleared reversible inhibitors.2 Collectively, results from the current work provide credence to the incorporation of isoform‐specific UGT metabolism and inhibition data into a mechanistic PBPK model for the prediction of herb–drug interactions mediated via inhibition of intestinal glucuronidation.","label":[[34,43,"Herb name"],[44,54,"Drug"],[104,114,"Drug"],[104,132,"Parameter"],[152,161,"Herb name"],[488,508,"Parameter"],[642,668,"Parameter"]],"Comments":[]}
{"id":2160,"text":"In general, the proof‐of‐concept clinical study suggested a low interaction risk of silibinin administered with raloxifene.","label":[[12,47,"Study"],[84,93,"Herb name"],[112,122,"Drug"]],"Comments":[]}
{"id":2161,"text":"These data are consistent with evaluation of herbal products as inhibitors of hepatic glucuronidation in healthy volunteers43, 44, 45, 46, 47 and support the assertion that drug interaction risk for UGT substrates is generally low.48 However, multiple subjects demonstrated nearly 2‐fold increases in raloxifene exposure, suggesting that the interaction potential should not be disregarded entirely.","label":[[78,101,"Parameter"],[105,112,"Pathology"],[199,202,"Parameter"],[301,311,"Drug"],[301,320,"Parameter"]],"Comments":[]}
{"id":2162,"text":"Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.","label":[[35,44,"Herb name"],[59,74,"Frequency"],[78,88,"Drug"]],"Comments":[]}
{"id":2163,"text":"One subject demonstrated high baseline raloxifene AUC PBPK modeling is an iterative process whereby the model should be updated with knowledge gained from clinical observations to enhance confidence and better predict unknown clinical situations.49, 50 Future applications of this modeling approach include alternate combinations of herbal product perpetrators and drug victims.","label":[[39,49,"Drug"],[39,53,"Parameter"],[333,360,"Herb name"],[365,377,"Drug"]],"Comments":[]}
{"id":2164,"text":"Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.","label":[],"Comments":[]}
{"id":2165,"text":"As a result, these modeling approaches may also be useful in the evaluation of drug–drug interaction potential of new chemical entities cleared predominantly by glucuronidation.","label":[],"Comments":[]}
{"id":2166,"text":"In summary, quantitative prediction of herb–drug interactions remains challenging.","label":[],"Comments":[]}
{"id":2167,"text":"This work evaluated the application of a quantitative framework to assess the risk of an herb–drug interaction mediated via a mechanism not previously explored in humans.","label":[],"Comments":[]}
{"id":2168,"text":"Model‐informed clinical evaluation of the silibinin–raloxifene interaction indicated minimal clinical interaction liability, albeit some individuals may be more sensitive for as‐yet unknown reasons.","label":[[42,51,"Herb name"],[52,62,"Drug"]],"Comments":[]}
{"id":2169,"text":"Further development and validation of PBPK modeling and simulation approaches will enhance confidence in model predictions and facilitate generalizability to alternate combinations of herbal products and conventional drugs.","label":[[184,199,"Herb name"],[204,222,"Drug"]],"Comments":[]}
{"id":2170,"text":"Ultimately, these approaches can be used to establish paradigms for the prospective evaluation of herb–drug interaction potential that will provide evidence‐based information about the risk or safety of herb–drug combinations.","label":[],"Comments":[]}
{"id":2171,"text":"The authors have no disclosures and declare no personal or financial conflicts of interest.","label":[],"Comments":[]}
{"id":2172,"text":"B.T.G., J.R.W., J.T.B., N.H.O., and M.F.P.","label":[],"Comments":[]}
{"id":2173,"text":"wrote the article.","label":[],"Comments":[]}
{"id":2174,"text":"B.T.G.","label":[],"Comments":[]}
{"id":2175,"text":"and M.F.P.","label":[],"Comments":[]}
{"id":2176,"text":"designed research.","label":[],"Comments":[]}
{"id":2177,"text":"B.T.G., J.T.B., V.G.P., J.R.W., and M.E.L.","label":[],"Comments":[]}
{"id":2178,"text":"performed research.","label":[],"Comments":[]}
{"id":2179,"text":"B.T.G., N.H.O., and M.F.P.","label":[],"Comments":[]}
{"id":2180,"text":"analyzed data.","label":[],"Comments":[]}
{"id":2181,"text":"N.H.O.","label":[],"Comments":[]}
{"id":2182,"text":"contributed new reagents\/analytical tools.","label":[],"Comments":[]}
{"id":2183,"text":"Supporting Information Click here for additional data file.","label":[],"Comments":[]}
{"id":2184,"text":"Supporting Information Click here for additional data file.","label":[],"Comments":[]}
{"id":2185,"text":"Supporting Information Click here for additional data file.","label":[],"Comments":[]}
{"id":2186,"text":"Supporting Information Click here for additional data file.","label":[],"Comments":[]}
{"id":2187,"text":"Supporting Information Click here for additional data file.","label":[],"Comments":[]}
{"id":2188,"text":"Supporting Information Click here for additional data file.","label":[],"Comments":[]}
{"id":2189,"text":"The authors thank Judy Griffin and Yili Zhong (WSU) for their assistance in conducting the clinical study and Tyler Graf (UNCG) for verifying silibinin content in the test herbal product.","label":[[91,105,"Study"],[142,151,"Herb name"],[172,186,"Herb name"]],"Comments":[]}
{"id":2190,"text":"The Health Sciences and Services Authority of Spokane provided financial support to purchase bioanalytical instrumentation.","label":[],"Comments":[]}
{"id":2191,"text":"This work was supported by the National Institutes of Health National Institute of General Medical Sciences (Grant R01 GM077482‐S1).","label":[],"Comments":[]}
{"id":2192,"text":"B.T.G.","label":[],"Comments":[]}
{"id":2193,"text":"was supported by a fellowship awarded by the American Foundation for Pharmaceutical Education.","label":[],"Comments":[]}
{"id":2194,"text":"B.T.G.","label":[],"Comments":[]}
{"id":2195,"text":"is currently supported by the National Institute of General Medical Sciences (Grant T32 GM008425).","label":[],"Comments":[]}
{"id":2196,"text":"M.F.P.","label":[],"Comments":[]}
{"id":2197,"text":"dedicates this article to Dr. David P. Paine.","label":[],"Comments":[]}
